Besides chemotherapy, tamoxifen may also have immune-modulatory effects, potentially interfering with the prognostic effects of tumor-infiltrating immune cells, as anticipated when we developed a prognostic gene expression signature for ER-positive, HER2-negative patients treated with adjuvant endocrine therapy (EndoPredictTM) [17]. This evidence concerns the gene ESR1 and neoplasm.